89bio

Subsidiary of Roche (RHHBY)

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
FGFR1c/2c/3c–β-Klotho agonistProtein / enzyme therapeutic
MASH / NASHSevere Hypertriglyceridemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Est. primary completion 2028-06-30 · NCT06419374 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Est. primary completion 2029-02 · NCT06318169 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2—$104M$129M$112Mreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1—$64M$315M$71Mreport ↗
2024-Q3—$141M$91M$149Mreport ↗
2024-Q2—$45M$212M$48Mreport ↗
2024-Q1—$47M$218M$52Mreport ↗
2023-Q3—$31M$252M$35Mreport ↗
2023-Q2—$35M$245M$38Mreport ↗
2023-Q1—$22M$351M$29Mreport ↗
2022-Q3—$22M$72M$27Mreport ↗
2022-Q2—$20M$61M$25Mreport ↗
2022-Q1—$20M$55M$26Mreport ↗
2021-Q3—$24M$40M$28Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$345M$126M$92Mreport ↗

89bio reported R&D spend of $345.04M, up 182.3% YoY, cash and equivalents of $126.06M, and a net loss of $367.08M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$122M$316M$36Mreport ↗
2022-FY—$81M$55M$26Mreport ↗
2021-FY—$70M$52M$23Mreport ↗